NewsSource: EClinCloud

EClinCloud Named to the Top 5 Most Investable Companies in the Digital Economy

3 min readEClinCloud Editorial Team
一临云数字经济领域最具投资价值企业TOP5奖杯与覃龙创业先锋奖杯

Author: EClinCloud. Originally published on the EClinCloud WeChat official account on July 31, 2026.

Recently, the results of the 12th "Search for Ningbo's Most Investable Companies" selection were officially announced. EClinCloud stood out from more than 620 participating companies to be named among the Top 5 Most Investable Companies in the "Digital Economy" category. At the same time, the company's founder and CEO, Dr. Qin Long, received the "Entrepreneurial Pioneer" individual award, making EClinCloud a dual winner in this year's selection.

一临云数字经济领域最具投资价值企业TOP5奖杯与覃龙创业先锋奖杯

Innovation Capability and Commercial Value Recognized

Now in its twelfth edition, the "Search for Ningbo's Most Investable Companies" program is one of the most influential venture capital events in the Ningbo region. Guided by multiple government authorities including the Ningbo Municipal Local Financial Supervision and Administration Bureau, the Ningbo State-owned Assets Supervision and Administration Commission (SASAC), and the Ningbo Office of the China Banking and Insurance Regulatory Commission (CBIRC), the event aims to identify high-quality local Ningbo enterprises with strong growth potential and investment value and to build a bridge connecting industry and capital.

Centered on the theme of technology- and innovation-driven leadership and focused on new quality productive forces, the program covered emerging industry tracks such as intelligent manufacturing, artificial intelligence, the digital economy, and green and low-carbon development, attracting applications from more than 620 companies since its launch in March. Spanning several months and multiple rounds of screening, the selection process conducted a comprehensive, multi-dimensional evaluation of participating companies across innovation capability, growth potential, team strength, business model, and industry outlook.

EClinCloud stood out from the broad pool of applicants to rank among the top five in the digital economy category, reflecting strong recognition of its overall capabilities—including innovation and commercial value—as well as confidence in its future growth potential.

2026年第十二届寻找宁波最具投资价值企业活动现场

As an AI technology company in clinical research, EClinCloud remains committed to independent innovation. Across the full clinical trial lifecycle, it continues to advance the R&D and application of frontier technologies—including artificial intelligence, big data, and cloud computing—building a product portfolio that spans core operational scenarios such as data capture, project management, endpoint assessment, data governance, and intelligent analytics to provide global pharmaceutical and medical device companies, CROs, and research institutions with more intelligent, reliable, and compliant digital solutions.

EClinCloud will continue to strengthen its recruitment and development of AI talent, deepen the innovative application of AI across clinical research scenarios, accelerate its global expansion, and further build an integrated innovation system uniting technology, products, and services to create value for the high-quality advancement of clinical research.

EClinCloud's AI-Driven Product and Service Portfolio

  • eCOA
  • CTMS
  • eTMF
  • EDC
  • RTSM
  • RM
  • IRC
  • eLearning
  • Scale management
  • Rater training

About EClinCloud

EClinCloud is a leading AI company in the clinical research industry. Powered by AI, it builds an integrated intelligent clinical cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products—including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM—as well as scale management, linguistic validation, rater training, and data quality analysis services to deliver efficient and accurate digital solutions. Leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically assesses and helps improve the success rate of drug clinical trials, helping shorten drug and medical device R&D cycles to benefit patients.

EClinCloud original article footer image


Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.